Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

Novian Health Announces Agreement with Rose Medical Center in Denver

October 29, 2009 by Novian Health

October 29, 2009
Contact: Liz Dowling, (800) 386-0157
Dowling & Dennis Public Relations
E-mail: Liz@DowlingDennis.net

Leading Denver Hospital Among First in Country to Offer Novilase Breast Therapy

CHICAGO – Novian Health, manufacturer of Novilase™ Breast Therapy for benign breast tumors, announced an agreement with Rose Medical Center for Rose to provide the Novilase laser treatment to treat breast lumps.

“Rose Medical Center is recognized throughout the country for its breast health services,” said Henry R. Appelbaum, Novian Health’s President and CEO. “Their embrace of Novilase shows that leaders in breast health recognize the benefits this technology brings to their patients.”

The Rose agreement is one of several similar agreements that will be announced by Novian Health this year.Novilase is a minimally invasive procedure that uses heat from a laser to destroy benign breast tumors, or fibroadenomas. Fibroadenomas are prevalent in younger women. An alternative to surgery, Novilase is safe, effective, and less risky than lumpectomy while providing a superior cosmetic outcome. Novilase is FDA-cleared for this indication and is not an experimental procedure.

“We’re using Novilase for non-surgical removal of non-malignant tumors, but we see this as a stepping stone to using this same treatment for malignant tumors, as well,” said Barbara Schwartzberg, M.D., chairwoman of the Rose Medical Center Cancer Committee. “I believe we’re witnessing a major step toward even better treatment options for breast cancer patients.”

Novilase will be performed at the Rose Breast Center using only local anesthetic.The procedure is performed via two small probes inserted through tiny nicks in the skin.Only targeted tissue is destroyed. The skin nicks made for the procedure close with a bandage instead of sutures. After the treatment, the body’s natural process repairs the site by replacing ablated tissue with normal tissue.

Rose Medical Center is also participating in the American Breast Laser Ablation Tracking Evaluation (ABLATE) data collection program, to gather further clinical information about Novilase. Novilase is FDA-cleared and is not an experimental procedure.

About Rose Medical Center

Well known as a Denver institution for 60 years, HealthONE Rose Medical Center is a leader in comprehensive women’s, surgical and endoscopy services, heart and vascular, orthopedics,total joint replacement, bariatrics, and sports, internal and aesthetic medicine. By offering a high level of expertise and service across all disciplines, Rose has become a destination hospital, attracting patients from throughout Colorado and around the world.

Rose Medical Center was recently named one of the nation’s 100 Top Hospitals® by Thomson Reuters, a leading provider of information to improve the cost and quality of healthcare. The award recognizes hospitals that have achieved excellence in clinical outcomes, patient safety, patient satisfaction, financial performance, and operational efficiency. This was the fourth time that Rose was recognized with this honor.

About Novian Health

Novian Health Inc., located in Chicago, is a privately held company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT).The company’s minimally invasive Novilase procedure uses ILT (controlled heating) for the ablation of breast tumors as an alternative to the surgically invasive, traditional “lumpectomy.”

Novian Health received its first FDA 510(k) market clearance for treating fibroadenomas (benign tumors) of the breast and expects to offer its technology at centers around the country. Approval for treatment of malignant tumors will also be sought.
For more information, call (312) 266-7200 or access www.novianhealth.com.

Related Posts

  • Novian Health Announces Agreement with Tower Radiology Center in Tampa Bay
  • Novian Health Presents at the “Investment in Innovation (IN3) Medical Device Summit: A Preview of Early-Stage Medical Technology Companies"TM
  • Novian Health Presents at William Blair Private Conference
  • Denver: Rose Medical Enters in Novilase Cancer Clinical Trial (12 April 2012)
  • Novian Health Awarded New Patent for Breast Cancer Treatment Technology (05 Dec 2013)

Filed Under: Archives

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by